XML 23 R15.htm IDEA: XBRL DOCUMENT v3.25.3

Supplementary Balance Sheet Information

9 Months Ended

Sep. 30, 2025

Balance Sheet Related Disclosures [Abstract]

Supplementary Balance Sheet Information

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):

		As of
		September 30, 2025				December 31, 2024
Lab equipment		$	6,236			$	5,854
Leasehold improvements			28,236				28,192
Computer equipment			1,150				1,305
Furniture and fixtures			1,122				1,100
Software			325				325
Vehicles			97				97
Construction in process			8				89
			37,174				36,962
Less accumulated depreciation			(11,712	)			(9,134	)
Total property and equipment, net		$	25,462			$	27,828

Depreciation expense was $0.9 million and $2.8 million for the three and nine months ended September 30, 2025, compared to $1.0 million and $2.8 million for the three and nine months ended September 30, 2024, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):

		September 30, 2025												December 31, 2024
		Cost				Accumulated Amortization				Net Carrying Value				Cost				Accumulated Amortization				Net Carrying Value
Intangible assets subject to amortization
Patents		$	1,944			$	(972	)		$	972			$	1,940			$	(877	)		$	1,063
Purchased technology			16,900				(13,614	)			3,286				16,900				(12,206	)			4,694
Intangible assets not subject to     amortization
Trademarks			117				—				117				117				—				117
Total		$	18,961			$	(14,586	)		$	4,375			$	18,957			$	(13,083	)		$	5,874

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.5 million for both the three and nine months ended September 30, 2025 and 2024, respectively.

Future estimated amortization expense of intangible assets is (in thousands):

		As of September 30, 2025
Remainder of 2025			507
2026			2,012
2027			1,055
2028			104
2029			95
2030 and thereafter			485
Total		$	4,258

Accrued liabilities consist of the following (in thousands):

		As of
		September 30, 2025				December 31, 2024
Compensation related accruals		$	6,946			$	6,770
Accrued clinical trial expenses			747				919
Other expenses			2,027				2,375
Total accrued liabilities		$	9,720			$	10,064

X

- References

No definition available.

+ Details

Name:	us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/210/tableOfContent

+ Details

Name:	us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration